# Endothelial cell responses in sepsis are attenuated by targeting truncated procalcitonin

**Authors:** Laura Brabenec, Katharina EM Hellenthal, Sebastian Kintrup, Laura Cyran, Philipp Burkard, Astrid Nottebaum, Klaus Schughart, Stefan Wagner, Roland Arnold, Vera Rauschenberger, Stefanie Kampmeier, Patrick Meybohm, Nicolas Schlegel, Dietmar Vestweber, Nana-Maria Wagner

PMC · DOI: 10.1038/s41467-025-68199-x · 2026-01-21

## TL;DR

Blocking truncated procalcitonin helps protect blood vessels and organs in sepsis by reducing inflammation and improving vascular function in mice.

## Contribution

This study demonstrates that targeting truncated procalcitonin preserves endothelial function and reduces sepsis severity in mice.

## Key findings

- Anti-procalcitonin antibodies reduced endothelial gene changes by over 50% in septic mice.
- Neutralizing procalcitonin preserved vascular integrity and reduced organ injury in sepsis.
- Procalcitonin neutralization decreased interleukin-17 signaling in septic mice.

## Abstract

Sepsis is associated with hypotension, vascular leakage, vasoplegia and microvascular dysfunction. Therefore, the endothelium is a target for sepsis therapies. Since truncated procalcitonin exerts vascular activity, we here evaluated the efficacy of targeting procalcitonin for vascular integrity and sepsis outcomes. Sepsis up-regulated >2000 genes involved in pro-inflammatory responses while similar numbers of genes involving cell growth and maintenance were down-regulated. Transcriptomic changes in endothelial cells diminished by >50% by anti-procalcitonin antibodies and this was functionally associated with preserved vascular barrier integrity in lungs and intestines, reduced sepsis-induced vasoplegia, preserved endothelial nitric oxide bioavailability, improved organ integrity and reduced sepsis severity in mice. Mechanistically, procalcitonin neutralization was associated with reduced signaling of the interleukin-17 pathway. We here show sepsis induces substantial changes to the endothelial transcriptome and vascular integrity and neutralizing procalcitonin is a suitable means to preserve endothelial homeostasis at a transcriptomic and functional level that could translate into organ protection during sepsis.

Sepsis causes endothelial dysfunction that drives vascular failure and organ injury. Here the authors show that neutralizing truncated procalcitonin reduced pro-inflammatory activation and leakage in the endothelium, resulting in preserved organ integrity, improved clinical outcomes and predicted survival in septic mice.

## Linked entities

- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Il17a (interleukin 17A) [NCBI Gene 16171] {aka Ctla-8, Ctla8, IL-17, IL-17A, Il17}, Tmprss15 (transmembrane protease, serine 15) [NCBI Gene 19146] {aka Entk, Prss7}, Dpp4 (dipeptidylpeptidase 4) [NCBI Gene 13482] {aka Cd26, Dpp-4, THAM}, Calca (calcitonin/calcitonin-related polypeptide, alpha) [NCBI Gene 12310] {aka CA, CGRP-1, CGRP1, Calc, Calc1, Cgrp}, Il17f (interleukin 17F) [NCBI Gene 257630] {aka IL-17F}, Icam1 (intercellular adhesion molecule 1) [NCBI Gene 15894] {aka CD54, Icam-1, Ly-47, MALA-2}, Gapdh (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 14433] {aka Gapd}, Calcrl (calcitonin receptor-like) [NCBI Gene 54598] {aka CRLR}, Alb (albumin) [NCBI Gene 11657] {aka Alb-1, Alb1, BCL001, BCL002, BPL001}, Cdh5 (cadherin 5) [NCBI Gene 12562] {aka 7B4, Cd144, VE-Cad, VECD, VEcad, Vec}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, Pecam1 (platelet/endothelial cell adhesion molecule 1) [NCBI Gene 18613] {aka Cd31, PECAM-1, Pecam}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, CALCA (calcitonin related polypeptide alpha) [NCBI Gene 796] {aka CALC1, CGRP, CGRP-I, CGRP-alpha, CGRP1, CT}, Vegfa (vascular endothelial growth factor A) [NCBI Gene 22339] {aka L-VEGF, Vegf, Vpf}, CALCRL (calcitonin receptor like receptor) [NCBI Gene 10203] {aka CGRPR, CRLR, LMPHM8}, RAMP1 (receptor activity modifying protein 1) [NCBI Gene 10267], Ramp1 (receptor (calcitonin) activity modifying protein 1) [NCBI Gene 51801] {aka 9130218E19Rik}, CALML3 (calmodulin like 3) [NCBI Gene 810] {aka CLP}, Il1 (interleukin 1 complex) [NCBI Gene 111343] {aka Il-1}, Vcam1 (vascular cell adhesion molecule 1) [NCBI Gene 22329] {aka CD106, Vcam-1}, Ptprc (protein tyrosine phosphatase receptor type C) [NCBI Gene 19264] {aka B220, CD45R, Cd45, L-CA, Ly-5, Lyt-4}, Pcts (plasmacytoma susceptibility) [NCBI Gene 107467], Vegfc (vascular endothelial growth factor C) [NCBI Gene 22341] {aka VEGF-C}
- **Diseases:** bacterial peritonitis (MESH:D010538), MODS (MESH:D009102), Sepsis (MESH:D018805), epithelial necrosis (MESH:D009375), Tubular injury (MESH:D000230), lethargy (MESH:D053609), Hypotension (MESH:D007022), tissue damage (MESH:D017695), Pulmonary edema (MESH:D011654), bacterial (MESH:D001424), vascular failure (MESH:D051437), vascular dysfunction (MESH:D002561), vasoplegia (MESH:D056987), liver and kidney injury (MESH:D017093), endothelial dysfunction (MESH:D014652), microvascular dysfunction (MESH:D017566), fungal (MESH:D009181), Hypovolemia (MESH:D020896), acute tubular injury (MESH:D001930), necrosis (MESH:D009336), acute lung injury (MESH:D055371), inflammation (MESH:D007249), diarrhea (MESH:D003967), kidney (MESH:D007674), septic (MESH:D001170), organ damage (MESH:D000092124), edema (MESH:D004487), immunological disorders (MESH:D007154), bacteremia (MESH:D016470), hepatic tissue damage (MESH:D056486), dehydration (MESH:D003681), death (MESH:D003643), ischemia (MESH:D007511)
- **Chemicals:** NO (MESH:D009569), Catecholamine (MESH:D002395), (R)-(-)-phenylephrine hydrochloride (-), sitagliptin (MESH:D000068900), MgCl2 (MESH:D015636), olcegepant (MESH:C406305), imidazole (MESH:C029899), Ca (MESH:D002118), IPTG (MESH:D007544), formaldehyde (MESH:D005557), SDS (MESH:D012967), Phe (MESH:D010649), glucose (MESH:D005947), carbamoylcholine (MESH:D002217), hydrocortisone (MESH:D006854), Agar (MESH:D000362), phenylephrine (MESH:D010656), Evans Blue (MESH:D005070), hematoxylin (MESH:D006416), MDA (MESH:D015104), dextran (MESH:D003911), formamide (MESH:C031066), HEPES (MESH:D006531), NaCl (MESH:D012965), KCl (MESH:D011189), LPS (MESH:D008070), PEB (MESH:C038328), tween 20 (MESH:D011136), BIBN4096 (MESH:C505165), EDTA (MESH:D004492), DMSO (MESH:D004121), CaCl2 (MESH:D002122), Poly(A) (MESH:D011061), eosin (MESH:D004801), thioglycolate (MESH:D013864), EGTA (MESH:D004533), FITC (MESH:D016650), PVDF (MESH:C024865), tyrosine (MESH:D014443)
- **Species:** Homo sapiens (human, species) [taxon 9606], Oryctolagus cuniculus (domestic rabbit, species) [taxon 9986], Mus musculus (house mouse, species) [taxon 10090]
- **Mutations:** C2987H, tyrosine residue 685
- **Cell lines:** BL21 — Homo sapiens (Human), EBV-related Burkitt lymphoma, Cancer cell line (CVCL_M639)

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12824222/full.md

---
Source: https://tomesphere.com/paper/PMC12824222